Valar Labs
Valar Labs is an AI and oncology company focused on improving cancer treatment decisions. Their AI diagnostics interpret solid tumors to provide clear, actionable reports on the likelihood of therapeutic response. Their flagship product, Vesta, is the first bladder cancer diagnostic to predict treatment response to BCG using routine histology. Valar Labs partners with pharmaceutical companies to accelerate early research by deploying AI algorithms for biomarker discovery and advancement. The company was founded with the belief that pathology is an untapped modality in cancer care, aiming to remove uncertainty for oncologists and patients in therapy selection. They have secured $22 million in Series A funding to advance Vesta and expand into other cancers.
Valar Labs
Valar Labs is an AI and oncology company focused on improving cancer treatment decisions. Their AI diagnostics interpret solid tumors to provide clear, actionable reports on the likelihood of therapeutic response. Their flagship product, Vesta, is the first bladder cancer diagnostic to predict treatment response to BCG using routine histology. Valar Labs partners with pharmaceutical companies to accelerate early research by deploying AI algorithms for biomarker discovery and advancement. The company was founded with the belief that pathology is an untapped modality in cancer care, aiming to remove uncertainty for oncologists and patients in therapy selection. They have secured $22 million in Series A funding to advance Vesta and expand into other cancers.